SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study
Background: Phase III clinical trials have documented the efficacy of the SARS-CoV-2 vaccines in preventing symptomatic COVID-19. Nonetheless, it is imperative to continue analyzing the clinical response to different vaccines in real-life studies. Our objective was to evaluate the effectiveness of f...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/12/1779 |
| _version_ | 1797379143451541504 |
|---|---|
| author | Ireri Thirión-Romero Rosario Fernández-Plata Midori Pérez-Kawabe Patricia A. Meza-Meneses Carlos Alberto Castro-Fuentes Norma E. Rivera-Martínez Eira Valeria Barrón-Palma Ana Laura Sánchez-Sandoval Patricia Cornejo-Juárez Jesús Sepúlveda-Delgado Darwin Stalin Torres-Erazo José Rogelio Pérez-Padilla |
| author_facet | Ireri Thirión-Romero Rosario Fernández-Plata Midori Pérez-Kawabe Patricia A. Meza-Meneses Carlos Alberto Castro-Fuentes Norma E. Rivera-Martínez Eira Valeria Barrón-Palma Ana Laura Sánchez-Sandoval Patricia Cornejo-Juárez Jesús Sepúlveda-Delgado Darwin Stalin Torres-Erazo José Rogelio Pérez-Padilla |
| author_sort | Ireri Thirión-Romero |
| collection | DOAJ |
| description | Background: Phase III clinical trials have documented the efficacy of the SARS-CoV-2 vaccines in preventing symptomatic COVID-19. Nonetheless, it is imperative to continue analyzing the clinical response to different vaccines in real-life studies. Our objective was to evaluate the effectiveness of five different vaccines in hospitalized patients with COVID-19 during the third COVID-19 outbreak in Mexico dominated by the Delta variant. Methods: A test-negative case–control study was performed in nine tertiary-care hospitals for COVID-19. We estimated odds ratios (OR) adjusted by variables related a priori with the likelihood of SARS-CoV-2 infection and its severity. Results: We studied 761 subjects, 371 cases, and 390 controls with a mean age of 53 years (SD, 17 years). Overall, 51% had a complete vaccination scheme, and an incomplete scheme (one dose from a scheme of two), 14%. After adjustment for age, gender, obesity, and diabetes mellitus, we found that the effectiveness of avoiding a SARS-CoV-2 infection when hospitalized with at least one vaccination dose was 71% (OR 0.29, 95% CI 0.19–0.45), that of an incomplete vaccination scheme, 67% (OR 0.33, 95% CI 0.18–0.62), and that of any complete vaccination scheme, 73% (OR 0.27, 95% CI 0.17–0.43). Conclusions: The SARS-CoV-2 vaccination program showed effectiveness in preventing SARS-CoV-2 infection in hospitalized patients during a Delta variant outbreak. |
| first_indexed | 2024-03-08T20:17:58Z |
| format | Article |
| id | doaj.art-3b330242b49444eca94834c5b9c0c38d |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-08T20:17:58Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-3b330242b49444eca94834c5b9c0c38d2023-12-22T14:47:04ZengMDPI AGVaccines2076-393X2023-11-011112177910.3390/vaccines11121779SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control StudyIreri Thirión-Romero0Rosario Fernández-Plata1Midori Pérez-Kawabe2Patricia A. Meza-Meneses3Carlos Alberto Castro-Fuentes4Norma E. Rivera-Martínez5Eira Valeria Barrón-Palma6Ana Laura Sánchez-Sandoval7Patricia Cornejo-Juárez8Jesús Sepúlveda-Delgado9Darwin Stalin Torres-Erazo10José Rogelio Pérez-Padilla11Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, MexicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, MexicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, MexicoHospital Regional de Alta Especialidad Ixtapaluca (HRAEI), Carretera Federal México-Puebla Km. 34.5, Pueblo de Zoquiapan, Ixtapaluca 56530, MexicoHospital Regional de Alta Especialidad Ixtapaluca (HRAEI), Carretera Federal México-Puebla Km. 34.5, Pueblo de Zoquiapan, Ixtapaluca 56530, MexicoHospital Regional de Alta Especialidad Oaxaca (HRAEO), C. Aldama s/n, Paraje El Tule, San Bartolo Coyotepec 71294, Oaxaca, MexicoHospital General de México (HGM) Eduardo Liceaga, Dr. Balmis 148, Doctores, Cuauhtémoc, Mexico City 06720, MexicoHospital General de México (HGM) Eduardo Liceaga, Dr. Balmis 148, Doctores, Cuauhtémoc, Mexico City 06720, MexicoInstituto Nacional de Cancerología (INCAN), Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, MexicoHospital Regional de Alta Especialidad Ciudad Salud (HRAECS), Carretera Tapachula Puerto Madero S/N km. 15 + 200, Carretera Federal 225, Col. Los Toros, Tapachula 30830, Chiapas, MexicoHospital Regional de Alta Especialidad Península de Yucatán (HRAEPY), C. 20 119, Col. Altabrisa, Merida 97130, Yucatán, MexicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER), Calz. de Tlalpan 4502, Belisario Domínguez Secc 16, Tlalpan, Mexico City 14080, MexicoBackground: Phase III clinical trials have documented the efficacy of the SARS-CoV-2 vaccines in preventing symptomatic COVID-19. Nonetheless, it is imperative to continue analyzing the clinical response to different vaccines in real-life studies. Our objective was to evaluate the effectiveness of five different vaccines in hospitalized patients with COVID-19 during the third COVID-19 outbreak in Mexico dominated by the Delta variant. Methods: A test-negative case–control study was performed in nine tertiary-care hospitals for COVID-19. We estimated odds ratios (OR) adjusted by variables related a priori with the likelihood of SARS-CoV-2 infection and its severity. Results: We studied 761 subjects, 371 cases, and 390 controls with a mean age of 53 years (SD, 17 years). Overall, 51% had a complete vaccination scheme, and an incomplete scheme (one dose from a scheme of two), 14%. After adjustment for age, gender, obesity, and diabetes mellitus, we found that the effectiveness of avoiding a SARS-CoV-2 infection when hospitalized with at least one vaccination dose was 71% (OR 0.29, 95% CI 0.19–0.45), that of an incomplete vaccination scheme, 67% (OR 0.33, 95% CI 0.18–0.62), and that of any complete vaccination scheme, 73% (OR 0.27, 95% CI 0.17–0.43). Conclusions: The SARS-CoV-2 vaccination program showed effectiveness in preventing SARS-CoV-2 infection in hospitalized patients during a Delta variant outbreak.https://www.mdpi.com/2076-393X/11/12/1779SARS-CoV-2 vaccinesvaccine effectivenessCOVID-19SARS-CoV-2 |
| spellingShingle | Ireri Thirión-Romero Rosario Fernández-Plata Midori Pérez-Kawabe Patricia A. Meza-Meneses Carlos Alberto Castro-Fuentes Norma E. Rivera-Martínez Eira Valeria Barrón-Palma Ana Laura Sánchez-Sandoval Patricia Cornejo-Juárez Jesús Sepúlveda-Delgado Darwin Stalin Torres-Erazo José Rogelio Pérez-Padilla SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study Vaccines SARS-CoV-2 vaccines vaccine effectiveness COVID-19 SARS-CoV-2 |
| title | SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study |
| title_full | SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study |
| title_fullStr | SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study |
| title_full_unstemmed | SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study |
| title_short | SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study |
| title_sort | sars cov 2 vaccine effectiveness in hospitalized patients a multicenter test negative case control study |
| topic | SARS-CoV-2 vaccines vaccine effectiveness COVID-19 SARS-CoV-2 |
| url | https://www.mdpi.com/2076-393X/11/12/1779 |
| work_keys_str_mv | AT irerithirionromero sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT rosariofernandezplata sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT midoriperezkawabe sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT patriciaamezameneses sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT carlosalbertocastrofuentes sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT normaeriveramartinez sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT eiravaleriabarronpalma sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT analaurasanchezsandoval sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT patriciacornejojuarez sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT jesussepulvedadelgado sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT darwinstalintorreserazo sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy AT joserogelioperezpadilla sarscov2vaccineeffectivenessinhospitalizedpatientsamulticentertestnegativecasecontrolstudy |